Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PolyPEPI (Bladder Cancer)
- Development stage
- Preclinical
- Lead developer
- Treos Bio
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
PolyPEPI (Bladder Cancer) is an off-the-shelf peptide-based cancer immunotherapy developed by Treos Bio for the treatment of bladder cancer. The therapy is based on the proprietary PolyPEPI platform, which utilizes the PASCal computational tool to identify and design synthetic peptides known as Personal EPItopes (PEPIs). These peptides are selected to match the human leukocyte antigen (HLA) recognition mechanisms of a broad patient population, aiming to induce robust and specific T-cell responses against tumor-associated antigens. The program has completed preclinical development and is part of a broader pipeline of peptide immunotherapies targeting various solid tumors, including colorectal, ovarian, and breast cancers.
- Other names
- PolyPEPI-bladder cancer
Beyond the preview
Go deeper on PolyPEPI (Bladder Cancer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PolyPEPI (Bladder Cancer).